Aegerion expects to file in US, Europe by year end for lomitapide for rare lipid disorder
This article was originally published in Scrip
Executive Summary
Aegerion Pharmaceuticals, a biotech focused on treating severe lipid disorders, has reported positive Phase III data for its oral MTP inhibitor, lomitapide, in an open label study of patients with homozygous familial hypercholesterolemia (hoFH), a rare genetic disorder involving extremely high LDL-C levels – with the full data showing a 44% reduction in LDL-C from baseline at 56 weeks.